Atezolizumab Approved for Initial Treatment of Metastatic Lung Cancer


On December 6, 2018, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with a standard three-drug regimen as an initial treatment for advanced lung cancer that does not have EGFR or ALK mutations.

Powered by WPeMatico